nodes	percent_of_prediction	percent_of_DWPC	metapath
Floxuridine—stomach cancer—esophageal cancer	0.351	1	CtDrD
Floxuridine—TYMP—esophageal cancer	0.294	1	CbGaD
Floxuridine—TYMP—Capecitabine—esophageal cancer	0.186	0.586	CbGbCtD
Floxuridine—TYMS—Capecitabine—esophageal cancer	0.0991	0.312	CbGbCtD
Floxuridine—TYMS—Methotrexate—esophageal cancer	0.0324	0.102	CbGbCtD
Floxuridine—TYMP—Fluoropyrimidine Activity—XRCC3—esophageal cancer	0.00137	0.0888	CbGpPWpGaD
Floxuridine—Nail changes—Capecitabine—esophageal cancer	0.00126	0.0872	CcSEcCtD
Floxuridine—Trifluridine—TYMP—esophageal cancer	0.000951	0.782	CrCbGaD
Floxuridine—Nail changes—Methotrexate—esophageal cancer	0.000936	0.0649	CcSEcCtD
Floxuridine—TYMP—Fluoropyrimidine Activity—CYP2A6—esophageal cancer	0.000797	0.0516	CbGpPWpGaD
Floxuridine—TYMS—Pyrimidine metabolism—TYMP—esophageal cancer	0.000758	0.0491	CbGpPWpGaD
Floxuridine—TYMP—bronchus—esophageal cancer	0.000751	0.125	CbGeAlD
Floxuridine—TYMP—smooth muscle tissue—esophageal cancer	0.000735	0.122	CbGeAlD
Floxuridine—TYMS—Fluoropyrimidine Activity—XRCC3—esophageal cancer	0.000701	0.0454	CbGpPWpGaD
Floxuridine—TYMP—trachea—esophageal cancer	0.000674	0.112	CbGeAlD
Floxuridine—TYMP—Fluoropyrimidine Activity—SMUG1—esophageal cancer	0.000649	0.042	CbGpPWpGaD
Floxuridine—TYMS—bronchus—esophageal cancer	0.000644	0.107	CbGeAlD
Floxuridine—TYMS—smooth muscle tissue—esophageal cancer	0.00063	0.105	CbGeAlD
Floxuridine—Duodenitis—Capecitabine—esophageal cancer	0.000621	0.0431	CcSEcCtD
Floxuridine—TYMS—Fluoropyrimidine Activity—TYMP—esophageal cancer	0.000588	0.0381	CbGpPWpGaD
Floxuridine—TYMP—digestive system—esophageal cancer	0.00058	0.0962	CbGeAlD
Floxuridine—Enteritis—Capecitabine—esophageal cancer	0.000534	0.037	CcSEcCtD
Floxuridine—Arterial thrombosis—Methotrexate—esophageal cancer	0.000504	0.035	CcSEcCtD
Floxuridine—TYMS—digestive system—esophageal cancer	0.000498	0.0826	CbGeAlD
Floxuridine—TYMP—lung—esophageal cancer	0.000485	0.0804	CbGeAlD
Floxuridine—TYMS—lung—esophageal cancer	0.000416	0.0689	CbGeAlD
Floxuridine—TYMS—Fluoropyrimidine Activity—CYP2A6—esophageal cancer	0.000407	0.0264	CbGpPWpGaD
Floxuridine—Enteritis—Methotrexate—esophageal cancer	0.000398	0.0276	CcSEcCtD
Floxuridine—TYMP—Bladder Cancer—RB1—esophageal cancer	0.00037	0.024	CbGpPWpGaD
Floxuridine—TYMS—Fluoropyrimidine Activity—SMUG1—esophageal cancer	0.000332	0.0215	CbGpPWpGaD
Floxuridine—TYMP—lymph node—esophageal cancer	0.000331	0.055	CbGeAlD
Floxuridine—TYMP—Bladder Cancer—CDKN2A—esophageal cancer	0.000325	0.0211	CbGpPWpGaD
Floxuridine—Abscess—Cisplatin—esophageal cancer	0.000313	0.0217	CcSEcCtD
Floxuridine—TYMP—Bladder Cancer—ERBB2—esophageal cancer	0.000311	0.0201	CbGpPWpGaD
Floxuridine—Infection—Carboplatin—esophageal cancer	0.000299	0.0207	CcSEcCtD
Floxuridine—TYMS—Nucleotide metabolism—TYMP—esophageal cancer	0.000295	0.0191	CbGpPWpGaD
Floxuridine—TYMS—lymph node—esophageal cancer	0.000284	0.0472	CbGeAlD
Floxuridine—Embolism—Capecitabine—esophageal cancer	0.000284	0.0197	CcSEcCtD
Floxuridine—Nail disorder—Capecitabine—esophageal cancer	0.000281	0.0195	CcSEcCtD
Floxuridine—TYMP—Bladder Cancer—CCND1—esophageal cancer	0.000275	0.0178	CbGpPWpGaD
Floxuridine—TYMS—E2F transcription factor network—XRCC1—esophageal cancer	0.00027	0.0175	CbGpPWpGaD
Floxuridine—TYMP—Bladder Cancer—CDKN1A—esophageal cancer	0.000266	0.0172	CbGpPWpGaD
Floxuridine—Body temperature increased—Carboplatin—esophageal cancer	0.000238	0.0165	CcSEcCtD
Floxuridine—Myocardial ischaemia—Capecitabine—esophageal cancer	0.000227	0.0157	CcSEcCtD
Floxuridine—TYMP—Bladder Cancer—MYC—esophageal cancer	0.00022	0.0143	CbGpPWpGaD
Floxuridine—TYMP—Bladder Cancer—EGFR—esophageal cancer	0.000216	0.014	CbGpPWpGaD
Floxuridine—Embolism—Methotrexate—esophageal cancer	0.000212	0.0147	CcSEcCtD
Floxuridine—Nail disorder—Methotrexate—esophageal cancer	0.000209	0.0145	CcSEcCtD
Floxuridine—Lacrimation increased—Capecitabine—esophageal cancer	0.000198	0.0137	CcSEcCtD
Floxuridine—TYMS—Circadian rythm related genes—CRTC1—esophageal cancer	0.000194	0.0126	CbGpPWpGaD
Floxuridine—Zidovudine—CYP2A6—esophageal cancer	0.000193	0.159	CrCbGaD
Floxuridine—TYMP—Bladder Cancer—TP53—esophageal cancer	0.000181	0.0117	CbGpPWpGaD
Floxuridine—TYMS—E2F mediated regulation of DNA replication—RB1—esophageal cancer	0.00018	0.0117	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.000176	0.0114	CbGpPWpGaD
Floxuridine—TYMP—Fluoropyrimidine Activity—TP53—esophageal cancer	0.000172	0.0112	CbGpPWpGaD
Floxuridine—Abscess—Methotrexate—esophageal cancer	0.000172	0.0119	CcSEcCtD
Floxuridine—Cramp muscle—Cisplatin—esophageal cancer	0.000162	0.0112	CcSEcCtD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—HMGB1—esophageal cancer	0.000155	0.0101	CbGpPWpGaD
Floxuridine—Thrombophlebitis—Capecitabine—esophageal cancer	0.000153	0.0106	CcSEcCtD
Floxuridine—Photosensitivity—Capecitabine—esophageal cancer	0.000151	0.0105	CcSEcCtD
Floxuridine—Gastroenteritis—Capecitabine—esophageal cancer	0.000149	0.0104	CcSEcCtD
Floxuridine—Pancytopenia—Cisplatin—esophageal cancer	0.000147	0.0102	CcSEcCtD
Floxuridine—Glossitis—Methotrexate—esophageal cancer	0.000147	0.0102	CcSEcCtD
Floxuridine—TYMS—G1/S Transition—PSME1—esophageal cancer	0.000146	0.00948	CbGpPWpGaD
Floxuridine—TYMS—G1/S Transition—PSME2—esophageal cancer	0.000146	0.00948	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.000137	0.00886	CbGpPWpGaD
Floxuridine—Lethargy—Capecitabine—esophageal cancer	0.000135	0.00937	CcSEcCtD
Floxuridine—Stomatitis—Cisplatin—esophageal cancer	0.000135	0.00936	CcSEcCtD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—ABL1—esophageal cancer	0.000129	0.00833	CbGpPWpGaD
Floxuridine—TYMS—Mitotic G1-G1/S phases—PSME2—esophageal cancer	0.000123	0.00799	CbGpPWpGaD
Floxuridine—TYMS—Mitotic G1-G1/S phases—PSME1—esophageal cancer	0.000123	0.00799	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle, Mitotic—AJUBA—esophageal cancer	0.000122	0.00788	CbGpPWpGaD
Floxuridine—Dry skin—Capecitabine—esophageal cancer	0.000121	0.00842	CcSEcCtD
Floxuridine—Gastritis—Capecitabine—esophageal cancer	0.000117	0.00813	CcSEcCtD
Floxuridine—Thrombophlebitis—Methotrexate—esophageal cancer	0.000114	0.0079	CcSEcCtD
Floxuridine—Photosensitivity—Methotrexate—esophageal cancer	0.000112	0.00779	CcSEcCtD
Floxuridine—Angina pectoris—Capecitabine—esophageal cancer	0.000111	0.00773	CcSEcCtD
Floxuridine—Alopecia—Cisplatin—esophageal cancer	0.00011	0.00762	CcSEcCtD
Floxuridine—TYMS—Cell Cycle—AJUBA—esophageal cancer	0.000109	0.00704	CbGpPWpGaD
Floxuridine—Pancytopenia—Capecitabine—esophageal cancer	0.000109	0.00754	CcSEcCtD
Floxuridine—Erythema—Cisplatin—esophageal cancer	0.000108	0.0075	CcSEcCtD
Floxuridine—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000104	0.00725	CcSEcCtD
Floxuridine—Muscle spasms—Cisplatin—esophageal cancer	0.000104	0.00722	CcSEcCtD
Floxuridine—Lethargy—Methotrexate—esophageal cancer	0.000101	0.00698	CcSEcCtD
Floxuridine—Ill-defined disorder—Cisplatin—esophageal cancer	0.0001	0.00696	CcSEcCtD
Floxuridine—Anaemia—Cisplatin—esophageal cancer	0.0001	0.00694	CcSEcCtD
Floxuridine—Stomatitis—Capecitabine—esophageal cancer	9.95e-05	0.0069	CcSEcCtD
Floxuridine—TYMS—Cell Cycle—MLH3—esophageal cancer	9.83e-05	0.00637	CbGpPWpGaD
Floxuridine—Malaise—Cisplatin—esophageal cancer	9.76e-05	0.00677	CcSEcCtD
Floxuridine—Leukopenia—Cisplatin—esophageal cancer	9.68e-05	0.00672	CcSEcCtD
Floxuridine—Epistaxis—Capecitabine—esophageal cancer	9.63e-05	0.00668	CcSEcCtD
Floxuridine—TYMS—E2F transcription factor network—CREBBP—esophageal cancer	9.58e-05	0.0062	CbGpPWpGaD
Floxuridine—TYMS—E2F transcription factor network—RB1—esophageal cancer	9.54e-05	0.00618	CbGpPWpGaD
Floxuridine—Agranulocytosis—Capecitabine—esophageal cancer	9.52e-05	0.00661	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	9.3e-05	0.00602	CbGpPWpGaD
Floxuridine—Haemoglobin—Capecitabine—esophageal cancer	9.21e-05	0.00639	CcSEcCtD
Floxuridine—Haemorrhage—Capecitabine—esophageal cancer	9.16e-05	0.00636	CcSEcCtD
Floxuridine—Discomfort—Cisplatin—esophageal cancer	9.1e-05	0.00631	CcSEcCtD
Floxuridine—Pharyngitis—Capecitabine—esophageal cancer	9.09e-05	0.00631	CcSEcCtD
Floxuridine—Anaphylactic shock—Cisplatin—esophageal cancer	8.83e-05	0.00613	CcSEcCtD
Floxuridine—TYMS—Fluoropyrimidine Activity—TP53—esophageal cancer	8.81e-05	0.0057	CbGpPWpGaD
Floxuridine—Infection—Cisplatin—esophageal cancer	8.77e-05	0.00609	CcSEcCtD
Floxuridine—Nervous system disorder—Cisplatin—esophageal cancer	8.66e-05	0.00601	CcSEcCtD
Floxuridine—TYMP—Metabolism—BLVRB—esophageal cancer	8.66e-05	0.00561	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—SLC52A3—esophageal cancer	8.66e-05	0.00561	CbGpPWpGaD
Floxuridine—Thrombocytopenia—Cisplatin—esophageal cancer	8.65e-05	0.006	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	8.5e-05	0.00551	CbGpPWpGaD
Floxuridine—TYMS—Circadian rythm related genes—GHRL—esophageal cancer	8.46e-05	0.00548	CbGpPWpGaD
Floxuridine—Anorexia—Cisplatin—esophageal cancer	8.42e-05	0.00584	CcSEcCtD
Floxuridine—TYMS—E2F transcription factor network—CDKN2A—esophageal cancer	8.39e-05	0.00543	CbGpPWpGaD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—RB1—esophageal cancer	8.29e-05	0.00537	CbGpPWpGaD
Floxuridine—Alopecia—Capecitabine—esophageal cancer	8.1e-05	0.00562	CcSEcCtD
Floxuridine—Pancytopenia—Methotrexate—esophageal cancer	8.09e-05	0.00561	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	8.09e-05	0.00524	CbGpPWpGaD
Floxuridine—Erythema—Capecitabine—esophageal cancer	7.98e-05	0.00553	CcSEcCtD
Floxuridine—Photosensitivity reaction—Methotrexate—esophageal cancer	7.78e-05	0.00539	CcSEcCtD
Floxuridine—Decreased appetite—Cisplatin—esophageal cancer	7.68e-05	0.00532	CcSEcCtD
Floxuridine—Muscle spasms—Capecitabine—esophageal cancer	7.67e-05	0.00532	CcSEcCtD
Floxuridine—Stomatitis—Methotrexate—esophageal cancer	7.41e-05	0.00514	CcSEcCtD
Floxuridine—Ill-defined disorder—Capecitabine—esophageal cancer	7.4e-05	0.00513	CcSEcCtD
Floxuridine—Anaemia—Capecitabine—esophageal cancer	7.37e-05	0.00511	CcSEcCtD
Floxuridine—TYMP—Metabolism—CA1—esophageal cancer	7.36e-05	0.00477	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—SLC10A2—esophageal cancer	7.36e-05	0.00477	CbGpPWpGaD
Floxuridine—Feeling abnormal—Cisplatin—esophageal cancer	7.28e-05	0.00505	CcSEcCtD
Floxuridine—Malaise—Capecitabine—esophageal cancer	7.19e-05	0.00499	CcSEcCtD
Floxuridine—Zidovudine—ABCB1—esophageal cancer	7.18e-05	0.0591	CrCbGaD
Floxuridine—Epistaxis—Methotrexate—esophageal cancer	7.17e-05	0.00497	CcSEcCtD
Floxuridine—Leukopenia—Capecitabine—esophageal cancer	7.14e-05	0.00495	CcSEcCtD
Floxuridine—Agranulocytosis—Methotrexate—esophageal cancer	7.09e-05	0.00492	CcSEcCtD
Floxuridine—Body temperature increased—Cisplatin—esophageal cancer	6.98e-05	0.00484	CcSEcCtD
Floxuridine—TYMS—G1/S Transition—RB1—esophageal cancer	6.92e-05	0.00448	CbGpPWpGaD
Floxuridine—TYMS—E2F transcription factor network—CDKN1A—esophageal cancer	6.86e-05	0.00444	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	6.85e-05	0.00444	CbGpPWpGaD
Floxuridine—Haemoglobin—Methotrexate—esophageal cancer	6.85e-05	0.00475	CcSEcCtD
Floxuridine—Haemorrhage—Methotrexate—esophageal cancer	6.82e-05	0.00473	CcSEcCtD
Floxuridine—Pharyngitis—Methotrexate—esophageal cancer	6.77e-05	0.0047	CcSEcCtD
Floxuridine—TYMP—Metabolism—CA2—esophageal cancer	6.73e-05	0.00436	CbGpPWpGaD
Floxuridine—Discomfort—Capecitabine—esophageal cancer	6.71e-05	0.00465	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	6.64e-05	0.0043	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	6.64e-05	0.0043	CbGpPWpGaD
Floxuridine—Confusional state—Capecitabine—esophageal cancer	6.56e-05	0.00455	CcSEcCtD
Floxuridine—TYMS—E2F transcription factor network—EP300—esophageal cancer	6.52e-05	0.00422	CbGpPWpGaD
Floxuridine—Hypersensitivity—Cisplatin—esophageal cancer	6.51e-05	0.00451	CcSEcCtD
Floxuridine—Infection—Capecitabine—esophageal cancer	6.47e-05	0.00449	CcSEcCtD
Floxuridine—Nervous system disorder—Capecitabine—esophageal cancer	6.38e-05	0.00443	CcSEcCtD
Floxuridine—Thrombocytopenia—Capecitabine—esophageal cancer	6.37e-05	0.00442	CcSEcCtD
Floxuridine—Asthenia—Cisplatin—esophageal cancer	6.34e-05	0.00439	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	6.28e-05	0.00407	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—PLCE1—esophageal cancer	6.26e-05	0.00405	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—ADH7—esophageal cancer	6.26e-05	0.00405	CbGpPWpGaD
Floxuridine—Anorexia—Capecitabine—esophageal cancer	6.2e-05	0.0043	CcSEcCtD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—CCND1—esophageal cancer	6.16e-05	0.00399	CbGpPWpGaD
Floxuridine—Diarrhoea—Cisplatin—esophageal cancer	6.04e-05	0.00419	CcSEcCtD
Floxuridine—Alopecia—Methotrexate—esophageal cancer	6.03e-05	0.00418	CcSEcCtD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—CDKN1A—esophageal cancer	5.96e-05	0.00386	CbGpPWpGaD
Floxuridine—Erythema—Methotrexate—esophageal cancer	5.94e-05	0.00412	CcSEcCtD
Floxuridine—TYMS—Mitotic G1-G1/S phases—RB1—esophageal cancer	5.83e-05	0.00378	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle, Mitotic—HIST1H2BM—esophageal cancer	5.83e-05	0.00377	CbGpPWpGaD
Floxuridine—TYMS—E2F transcription factor network—MYC—esophageal cancer	5.68e-05	0.00368	CbGpPWpGaD
Floxuridine—Decreased appetite—Capecitabine—esophageal cancer	5.66e-05	0.00392	CcSEcCtD
Floxuridine—Vomiting—Cisplatin—esophageal cancer	5.61e-05	0.00389	CcSEcCtD
Floxuridine—Rash—Cisplatin—esophageal cancer	5.57e-05	0.00386	CcSEcCtD
Floxuridine—Dermatitis—Cisplatin—esophageal cancer	5.56e-05	0.00386	CcSEcCtD
Floxuridine—Ill-defined disorder—Methotrexate—esophageal cancer	5.51e-05	0.00382	CcSEcCtD
Floxuridine—TYMP—Metabolism—ADH1B—esophageal cancer	5.49e-05	0.00355	CbGpPWpGaD
Floxuridine—Anaemia—Methotrexate—esophageal cancer	5.49e-05	0.00381	CcSEcCtD
Floxuridine—Feeling abnormal—Capecitabine—esophageal cancer	5.36e-05	0.00372	CcSEcCtD
Floxuridine—Malaise—Methotrexate—esophageal cancer	5.35e-05	0.00371	CcSEcCtD
Floxuridine—Gastrointestinal pain—Capecitabine—esophageal cancer	5.32e-05	0.00369	CcSEcCtD
Floxuridine—Leukopenia—Methotrexate—esophageal cancer	5.31e-05	0.00369	CcSEcCtD
Floxuridine—Nausea—Cisplatin—esophageal cancer	5.24e-05	0.00364	CcSEcCtD
Floxuridine—TYMS—Cell Cycle—HIST1H2BM—esophageal cancer	5.21e-05	0.00338	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle, Mitotic—MAD2L1—esophageal cancer	5.15e-05	0.00333	CbGpPWpGaD
Floxuridine—Body temperature increased—Capecitabine—esophageal cancer	5.15e-05	0.00357	CcSEcCtD
Floxuridine—Abdominal pain—Capecitabine—esophageal cancer	5.15e-05	0.00357	CcSEcCtD
Floxuridine—TYMS—Mitotic G1-G1/S phases—CDKN2A—esophageal cancer	5.13e-05	0.00332	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—CYP26A1—esophageal cancer	5.1e-05	0.0033	CbGpPWpGaD
Floxuridine—Discomfort—Methotrexate—esophageal cancer	4.99e-05	0.00346	CcSEcCtD
Floxuridine—TYMS—G1/S Transition—CDKN1A—esophageal cancer	4.97e-05	0.00322	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—ALOX15—esophageal cancer	4.97e-05	0.00322	CbGpPWpGaD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—MYC—esophageal cancer	4.94e-05	0.0032	CbGpPWpGaD
Floxuridine—Confusional state—Methotrexate—esophageal cancer	4.89e-05	0.00339	CcSEcCtD
Floxuridine—Anaphylactic shock—Methotrexate—esophageal cancer	4.85e-05	0.00336	CcSEcCtD
Floxuridine—Infection—Methotrexate—esophageal cancer	4.81e-05	0.00334	CcSEcCtD
Floxuridine—Hypersensitivity—Capecitabine—esophageal cancer	4.8e-05	0.00333	CcSEcCtD
Floxuridine—Nervous system disorder—Methotrexate—esophageal cancer	4.75e-05	0.0033	CcSEcCtD
Floxuridine—Thrombocytopenia—Methotrexate—esophageal cancer	4.74e-05	0.00329	CcSEcCtD
Floxuridine—TYMP—Metabolism—TPI1—esophageal cancer	4.74e-05	0.00307	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—GSTO1—esophageal cancer	4.74e-05	0.00307	CbGpPWpGaD
Floxuridine—TYMS—Circadian rythm related genes—NOS2—esophageal cancer	4.74e-05	0.00307	CbGpPWpGaD
Floxuridine—Asthenia—Capecitabine—esophageal cancer	4.67e-05	0.00324	CcSEcCtD
Floxuridine—Anorexia—Methotrexate—esophageal cancer	4.62e-05	0.0032	CcSEcCtD
Floxuridine—TYMS—Cell Cycle—MAD2L1—esophageal cancer	4.6e-05	0.00298	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—ALDOB—esophageal cancer	4.55e-05	0.00294	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle, Mitotic—PSME1—esophageal cancer	4.52e-05	0.00293	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle, Mitotic—PSME2—esophageal cancer	4.52e-05	0.00293	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	4.46e-05	0.00289	CbGpPWpGaD
Floxuridine—Diarrhoea—Capecitabine—esophageal cancer	4.45e-05	0.00309	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	4.44e-05	0.00287	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—SLC52A3—esophageal cancer	4.43e-05	0.00287	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—BLVRB—esophageal cancer	4.43e-05	0.00287	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—GAPDH—esophageal cancer	4.38e-05	0.00283	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—CRABP1—esophageal cancer	4.34e-05	0.00281	CbGpPWpGaD
Floxuridine—TYMS—Mitotic G1-G1/S phases—CCND1—esophageal cancer	4.33e-05	0.00281	CbGpPWpGaD
Floxuridine—Decreased appetite—Methotrexate—esophageal cancer	4.21e-05	0.00292	CcSEcCtD
Floxuridine—TYMS—Mitotic G1-G1/S phases—CDKN1A—esophageal cancer	4.19e-05	0.00271	CbGpPWpGaD
Floxuridine—Vomiting—Capecitabine—esophageal cancer	4.14e-05	0.00287	CcSEcCtD
Floxuridine—TYMP—Metabolism—GNG7—esophageal cancer	4.13e-05	0.00267	CbGpPWpGaD
Floxuridine—TYMS—G1/S Transition—MYC—esophageal cancer	4.12e-05	0.00267	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle, Mitotic—BUB1B—esophageal cancer	4.12e-05	0.00267	CbGpPWpGaD
Floxuridine—Rash—Capecitabine—esophageal cancer	4.1e-05	0.00285	CcSEcCtD
Floxuridine—Dermatitis—Capecitabine—esophageal cancer	4.1e-05	0.00284	CcSEcCtD
Floxuridine—Headache—Capecitabine—esophageal cancer	4.08e-05	0.00283	CcSEcCtD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—TP53—esophageal cancer	4.06e-05	0.00263	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—PSME1—esophageal cancer	4.04e-05	0.00262	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—PSME2—esophageal cancer	4.04e-05	0.00262	CbGpPWpGaD
Floxuridine—Feeling abnormal—Methotrexate—esophageal cancer	3.99e-05	0.00277	CcSEcCtD
Floxuridine—Gastrointestinal pain—Methotrexate—esophageal cancer	3.96e-05	0.00275	CcSEcCtD
Floxuridine—TYMP—Metabolism—ALDH2—esophageal cancer	3.87e-05	0.0025	CbGpPWpGaD
Floxuridine—Nausea—Capecitabine—esophageal cancer	3.87e-05	0.00268	CcSEcCtD
Floxuridine—Body temperature increased—Methotrexate—esophageal cancer	3.83e-05	0.00266	CcSEcCtD
Floxuridine—Abdominal pain—Methotrexate—esophageal cancer	3.83e-05	0.00266	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	3.82e-05	0.00248	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—CA1—esophageal cancer	3.77e-05	0.00244	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—SLC10A2—esophageal cancer	3.77e-05	0.00244	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	3.72e-05	0.00241	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—BUB1B—esophageal cancer	3.68e-05	0.00238	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—GSTT1—esophageal cancer	3.68e-05	0.00238	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—CYP2A6—esophageal cancer	3.64e-05	0.00235	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	3.63e-05	0.00235	CbGpPWpGaD
Floxuridine—Hypersensitivity—Methotrexate—esophageal cancer	3.57e-05	0.00248	CcSEcCtD
Floxuridine—TYMS—Cell Cycle—CHEK2—esophageal cancer	3.5e-05	0.00227	CbGpPWpGaD
Floxuridine—Asthenia—Methotrexate—esophageal cancer	3.48e-05	0.00241	CcSEcCtD
Floxuridine—TYMS—Mitotic G1-G1/S phases—MYC—esophageal cancer	3.48e-05	0.00225	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—ENO1—esophageal cancer	3.45e-05	0.00223	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—PTGS1—esophageal cancer	3.45e-05	0.00223	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—CA2—esophageal cancer	3.44e-05	0.00223	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—PSME1—esophageal cancer	3.4e-05	0.0022	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—PSME2—esophageal cancer	3.4e-05	0.0022	CbGpPWpGaD
Floxuridine—Diarrhoea—Methotrexate—esophageal cancer	3.32e-05	0.0023	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	3.28e-05	0.00213	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—ADH7—esophageal cancer	3.2e-05	0.00207	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—PLCE1—esophageal cancer	3.2e-05	0.00207	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	3.18e-05	0.00206	CbGpPWpGaD
Floxuridine—Vomiting—Methotrexate—esophageal cancer	3.08e-05	0.00214	CcSEcCtD
Floxuridine—Rash—Methotrexate—esophageal cancer	3.06e-05	0.00212	CcSEcCtD
Floxuridine—Dermatitis—Methotrexate—esophageal cancer	3.05e-05	0.00212	CcSEcCtD
Floxuridine—Headache—Methotrexate—esophageal cancer	3.04e-05	0.00211	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	3.02e-05	0.00196	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—CYP1B1—esophageal cancer	2.93e-05	0.0019	CbGpPWpGaD
Floxuridine—TYMS—Circadian rythm related genes—EP300—esophageal cancer	2.9e-05	0.00188	CbGpPWpGaD
Floxuridine—Nausea—Methotrexate—esophageal cancer	2.88e-05	0.002	CcSEcCtD
Floxuridine—TYMS—Metabolism—ADH1B—esophageal cancer	2.81e-05	0.00182	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—CYP19A1—esophageal cancer	2.76e-05	0.00178	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—TYMP—esophageal cancer	2.68e-05	0.00174	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	2.63e-05	0.00171	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—CYP26A1—esophageal cancer	2.61e-05	0.00169	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	2.58e-05	0.00167	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—ALOX15—esophageal cancer	2.54e-05	0.00165	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—HMOX1—esophageal cancer	2.51e-05	0.00163	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—TPI1—esophageal cancer	2.43e-05	0.00157	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—GSTO1—esophageal cancer	2.43e-05	0.00157	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—ABCB1—esophageal cancer	2.41e-05	0.00156	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—ALDOB—esophageal cancer	2.33e-05	0.00151	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—GAPDH—esophageal cancer	2.24e-05	0.00145	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.24e-05	0.00145	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—CRABP1—esophageal cancer	2.22e-05	0.00144	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.16e-05	0.0014	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle, Mitotic—RB1—esophageal cancer	2.14e-05	0.00139	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—GNG7—esophageal cancer	2.11e-05	0.00137	CbGpPWpGaD
Floxuridine—TYMS—Circadian rythm related genes—TP53—esophageal cancer	2.08e-05	0.00134	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—ALDH2—esophageal cancer	1.98e-05	0.00128	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—RB1—esophageal cancer	1.91e-05	0.00124	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—GSTT1—esophageal cancer	1.88e-05	0.00122	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle, Mitotic—CDKN2A—esophageal cancer	1.88e-05	0.00122	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—CYP2A6—esophageal cancer	1.86e-05	0.0012	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—ENO1—esophageal cancer	1.76e-05	0.00114	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—PTGS1—esophageal cancer	1.76e-05	0.00114	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—PSME2—esophageal cancer	1.74e-05	0.00113	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—PSME1—esophageal cancer	1.74e-05	0.00113	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—CDKN2A—esophageal cancer	1.68e-05	0.00109	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—CREBBP—esophageal cancer	1.61e-05	0.00104	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle, Mitotic—CCND1—esophageal cancer	1.59e-05	0.00103	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle, Mitotic—CDKN1A—esophageal cancer	1.54e-05	0.000996	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—CYP1B1—esophageal cancer	1.5e-05	0.000971	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle, Mitotic—EP300—esophageal cancer	1.46e-05	0.000947	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—NOS3—esophageal cancer	1.44e-05	0.000935	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—CCND1—esophageal cancer	1.42e-05	0.00092	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—CYP19A1—esophageal cancer	1.41e-05	0.000913	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—CDKN1A—esophageal cancer	1.37e-05	0.00089	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—PTGS2—esophageal cancer	1.32e-05	0.000855	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—EP300—esophageal cancer	1.31e-05	0.000847	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—HMOX1—esophageal cancer	1.29e-05	0.000833	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle, Mitotic—MYC—esophageal cancer	1.27e-05	0.000825	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—ABCB1—esophageal cancer	1.23e-05	0.000799	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—MYC—esophageal cancer	1.14e-05	0.000738	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—EP300—esophageal cancer	1.1e-05	0.000711	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—TP53—esophageal cancer	9.36e-06	0.000606	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—CREBBP—esophageal cancer	8.25e-06	0.000534	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—PIK3CA—esophageal cancer	8.13e-06	0.000526	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—NOS3—esophageal cancer	7.39e-06	0.000478	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—PTGS2—esophageal cancer	6.76e-06	0.000438	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—EP300—esophageal cancer	5.62e-06	0.000364	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—PIK3CA—esophageal cancer	4.16e-06	0.000269	CbGpPWpGaD
